News Conference News ACC 2014 TAVR With the CoreValve Device Superior to Surgery at 1 Year Yael L. Maxwell March 29, 2014
News Conference News AHA 2013 Risk of Kidney Injury Not Affected by High-Potency Statin Regimen in ACS Patients Yael L. Maxwell November 20, 2013
News Conference News AHA 2013 French Registry: FFR Safely Reclassifies Almost Half of Revascularization Patients Yael L. Maxwell November 20, 2013
News Conference News AHA 2013 Renal Stenting Fails to Improve Outcomes vs. Medical Therapy Alone in RAS Patients Jason Kahn November 17, 2013
News Conference News AHA 2013 Long-term Outcomes with Renal Denervation Show Sustained Benefit Yael L. Maxwell November 16, 2013
News Conference News TCT 2013 Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias November 04, 2013
News Conference News TCT 2013 HYBRID: Hybrid Revascularization Shows Safety, Effectiveness vs. CABG in Multivessel CAD October 31, 2013
News Conference News TCT 2013 FREEDOM: Insulin Status Affects Revascularization Outcomes in Diabetic Patients October 31, 2013
News Conference News TCT 2013 SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach October 30, 2013
News Conference News TCT 2013 Renal Denervation Systems Show Persistent Reductions in BP October 30, 2013
News Conference News TCT 2013 EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI October 30, 2013
News Conference News TCT 2013 Transradial Approach Just as Safe, Effective as Transfemoral for Carotid Artery Stenting October 29, 2013
News Conference News TCT 2013 State of the Stent: PCI Future Intact Despite Costs, Sociopolitical Factors October 29, 2013
News Conference News TCT 2013 Early Data Show Promise of Endovascular Fistulas as Alternative to Surgical AVFs October 29, 2013
News Conference News TCT 2013 Preliminary Data Show Potential of Renal Denervation in Several Settings October 28, 2013
News Conference News ESC 2013 Symplicity Studies Support Safety, Efficacy of Percutaneous Renal Denervation Caitlin E. Cox September 04, 2013
News Conference News ESC 2013 PARTNER A: TAVR the Optimal Choice for Diabetic Patients at High Risk Yael L. Maxwell September 04, 2013
News Conference News ESC 2013 AQUARIUS: Aliskiren Fails Primary Endpoint But Surprises with MACE Reduction Caitlin E. Cox September 04, 2013